Advertisement
Research Articles

TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

Benjamin V. Park, Zachary T. Freeman, Ali Ghasemzadeh, Michael A. Chattergoon, Alleluiah Rutebemberwa, Jordana Steigner, Matthew E. Winter, Thanh V. Huynh, Suzanne M. Sebald, Se-Jin Lee, Fan Pan, Drew M. Pardoll and Andrea L. Cox
DOI: 10.1158/2159-8290.CD-15-1347 Published December 2016

Abstract

Programmed death-1 (PD-1) is a coinhibitory receptor that downregulates the activity of tumor-infiltrating lymphocytes (TIL) in cancer and of virus-specific T cells in chronic infection. The molecular mechanisms driving high PD-1 expression on TILs have not been fully investigated. We demonstrate that TGFβ1 enhances antigen-induced PD-1 expression through SMAD3-dependent, SMAD2-independent transcriptional activation in T cells in vitro and in TILs in vivo. The PD-1hi subset seen in CD8+ TILs is absent in Smad3-deficient tumor-specific CD8+ TILs, resulting in enhanced cytokine production by TILs and in draining lymph nodes and antitumor activity. In addition to TGFβ1′s previously known effects on T-cell function, our findings suggest that TGFβ1 mediates T-cell suppression via PD-1 upregulation in the tumor microenvironment (TME). They highlight bidirectional cross-talk between effector TILs and TGFβ-producing cells that upregulates multiple components of the PD-1 signaling pathway to inhibit antitumor immunity.

Significance: Engagement of the coinhibitory receptor PD-1 or its ligand, PD-L1, dramatically inhibits the antitumor function of TILs within the TME. Our findings represent a novel immunosuppressive function of TGFβ and demonstrate that TGFβ1 allows tumors to evade host immune responses in part through enhanced SMAD3-mediated PD-1 expression on TILs. Cancer Discov; 6(12); 1366–81. ©2016 AACR.

This article is highlighted in the In This Issue feature, p. 1293

Introduction

Programmed death-1 (PD-1; encoded by PDCD1) is a coinhibitory receptor induced on T cells by antigenic stimulation (1). PD-1 expression on functional memory CD8+ T cells declines upon the resolution of inflammation and the clearance of antigen during acute infections (2). Conversely, PD-1 expression is maintained on exhausted T cells in chronic infections. In cancer, the PD-1 pathway is highly engaged within the tumor microenvironment (TME), with tumor and immune system cells expressing high levels of the PD-1 ligands PD-L1 (also known as B7-H1) and PD-L2 (also known as B7-DC), and tumor-infiltrating CD4+ and CD8+ T cells expressing high levels of PD-1 (3, 4). Blockade of PD-1 has been effective in prolonging patient survival in melanoma, renal cell carcinoma, non–small cell lung cancers, Hodgkin lymphoma, and many other cancer types (5–8). Similarly, chronic infection with the hepatitis C virus (HCV), hepatitis B virus (HBV), or human immunodeficiency virus (HIV) sustains high levels of PD-1 on viral-specific CD8+ T cells (9–11).

Binding of PD-1 on T cells to its ligands, PD-L1 and PD-L2, can inhibit T-cell effector function (12). Pathogen- or tumor-driven inflammation can induce PD-L1 and PD-L2 expression. For example, PD-L1 is highly expressed on many human tumors (4, 13), and its expression is highly colocalized with infiltrating CD8+ T cells in patients with melanoma (14). Similarly, patients with chronic liver disease from HCV and HBV infection also show increased levels of PD-L1 on hepatocytes and Kupffer cells in the liver (15). Elevated PD-L1 and PD-L2 expression may enhance engagement of PD-1 on T cells and pathogen evasion of host immune responses (4, 16–19). The levels of PD-1 on tumor-infiltrating lymphocyte (TIL) subsets in many cancers are much higher than those seen on normally activated or memory T cells in peripheral blood or in corresponding normal tissue (20). This induction of receptor, together with ligand upregulation, is likely responsible for the profound inhibition of effector antitumor T-cell activity in the TME. Although IFNγ, a T-cell effector cytokine, is known to enhance PD-L1 expression on tumor cells (13), and some cytokines have been shown previously to affect T-cell expression of PD-1 (21, 22), the molecular mechanisms that permit expression of PD-1 on human T cells at very high levels have not been fully elucidated. This is critical to our understanding of PD-1 inhibition of T-cell control of tumors or chronic viral infections and modulation of that pathway through immunotherapy.

As part of a cytokine screen to identify those that regulate PD-1 induction on T cells, we found that TGFβ1 modified antigen-driven PD-1 induction to the greatest extent. TGFβ1 is a regulatory cytokine that suppresses immune function in cancers and in chronic viral infections (23–26). The SMAD transcription factors transduce signals from TGFβ superfamily ligands that regulate cell proliferation, differentiation, and death through the activation of receptor serine/threonine kinases. High serum levels of TGFβ are associated with poor prognosis in cancer (27, 28), and TME-derived TGFβ can suppress antitumor T-cell responses (29, 30). Accordingly, the blockade of TGFβ1 signaling on T cells has been effective in restoring T-cell effector functions (31, 32). The known suppressive mechanisms of TGFβ1 include SMAD2/3-dependent inhibition of effector cytokine production by CD8+ T cells in cancer (33) and development of CD4+ regulatory T cells (Treg) that suppress neighboring effector cells through both contact-independent and contact-dependent mechanisms (34, 35).

Here, we report a novel molecular mechanism of immunosuppression in which TGFβ enhances antigen-driven PD-1 gene transcription selectively through SMAD3, resulting in enhanced surface expression of PD-1 protein. Utilizing mice with T cells conditionally deleted of Smad2 or Smad3, we found that TGFβ1-enhanced PD-1 expression is abrogated in Smad3-deficent T cells. In contrast, Smad2-deficient T cells expressed PD-1 at levels comparable with wild-type (WT) mice. This suggests that enhanced PD-1 expression on T cells is predominantly regulated by SMAD3. The effect of SMAD3 was specific to PD-1, as the expression of other inhibitory receptors was not decreased by Smad3 deficiency. Mice with Smad3-deficient T cells more effectively controlled tumors in association with loss of the subset of antigen-specific TILs displaying the highest levels of PD-1 and increased TIL and draining lymph node (DLN) cytokine production. PD-1 blockade did not provide further antitumor activity beyond that produced by T cell–specific Smad3 knockout, demonstrating that PD-1 induction by the TGFβ1/SMAD3 axis is critical in suppressing antitumor T-cell function. Thus, our findings suggest that TME-derived TGFβ1 augments PD-1 expression on TILs, suppressing CD8+ T cells that engage tumor antigens and enhancing tumor immune resistance.

Results

TGFβ1 Enhances PD-1 Expression on Activated Human T Cells

To assess the effects of cytokines known to alter T-cell development, function, and/or proliferation on PD-1 expression, we isolated CD3+ T cells from healthy donor peripheral blood mononuclear cells (PBMC) and activated them with αCD3/αCD28–conjugated beads in the presence of one of 16 cytokines across a range of concentrations (Supplementary Fig. S1A, data shown at 500 ng/mL). The cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) to monitor cellular proliferation, and PD-1 expression was measured (Fig. 1A, representative plots). αCD3/αCD28 induces higher PD-1 expression compared with resting CD8+ and CD4+ T cells, confirming T-cell receptor (TCR) and costimulation-dependent PD-1 expression (Fig. 1A, left and middle graphs). Although most of the cytokines tested had no effect or only a modest effect on PD-1 expression upon T-cell activation, major enhancement of PD-1 expression was observed with TGFβ1 (Fig. 1A, middle and right graphs; and Supplementary Fig. S1A). In conjunction with T-cell stimulation, IL2, IL6, IL12, and TNFα induced only modest enhancement of αCD3/αCD28–induced PD-1 expression (Supplementary Fig. S1A). Because increased TGFβ1 production is a hallmark of most TME, we chose to further explore its role in PD-1 expression. The coculture of T cells with TGFβ1 further enhanced PD-1 expression on both CD8+ (Fig. 1B, left; open symbols) and CD4+ (Fig. 1B, right; open symbols) T cells versus αCD3/αCD28 alone (Fig. 1B, closed symbols) on all generations (Fig. 1B). TGFβ1 did not have any effects on cellular proliferation as measured by CFSE dilution (Fig. 1B, black vs. open bar graph), suggesting that enhanced PD-1 expression is not simply due to altered cellular proliferation.

Figure 1.
Figure 1.

TGFβ1 enhances PD-1 expression on human T cells in a dose-dependent manner. Human CD3+ T cells were isolated from healthy donor PBMCs and were activated with αCD3/αCD28–conjugated beads with or without TGFβ1 (50 ng/mL). A, Representative plots for PD-1 (y-axis) versus CFSE (x-axis) are shown for different conditions. B, PD-1 mean fluorescence intensity (MFI) is shown as filled circle lines (αCD3/αCD28) and open circle lines (αCD3/αCD28 + TGFβ1). The percentage of cells in each CFSE generation (G0, G1, G2, G3, and G4) is shown as black bar graphs (αCD3/αCD28) and white bar graphs (αCD3/αCD28 + TGFβ1). The data represent combined results of two independent trials. C, Naïve and memory subset of T cells (CD4+ and CD8+ T cells) were isolated on the basis of CCR7 and CD45RA expression and treated with αCD3/αCD28 activation in the presence or absence of TGFβ1. The representative histogram of PD-1 is shown. Isotype, shaded histogram; αCD3/αCD28, thin histogram; αCD3/αCD28 + TGFβ1, bold histogram. D, PD-1 MFI was assessed on each subset (x-axis) of CD8+ (left) and CD4+ (right) T cells; αCD3/αCD28 alone (black bars); αCD3/αCD28 with TGFβ1 (gray bars). The data represent combined results of two independent trials. E, Isolated human CD3+ T cells were activated with αCD3/αCD28–conjugated beads in the presence of varying concentrations of TGFβ1 (5–5 × 104 pg/mL). MFI of PD-1 (left) and HLA-DR (right) expressions was assessed in CD4+ (gray bars) and CD8+ (black bars) T cells. The shown result is the representative of at least three independent trials. F, PDCD1 transcript levels of human CD3+ T cells under different treatments were normalized to that of resting CD3+ T cells. The result is shown as mean ± SEM of technical replicates and is representative of at least three independent trials. The data were analyzed using the Student t test and considered significant if *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Although human memory T-cell populations, such as CMV- and EBV-specific T cells, express intermediate levels of PD-1, naïve T cells do not express PD-1 (36). To test whether TGFβ1-mediated enhancement of PD-1 expression depends on the basal level of PD-1 expression, we isolated naïve T cells (phenotype CCR7+ CD45RA+) and memory T cells (phenotype CCR7+ CD45RA− or CCR7− CD45RA+) from healthy donors. The cells were activated with αCD3/αCD28–conjugated beads with or without TGFβ1. Although TGFβ1 increased PD-1 expression on αCD3/βCD28–stimulated naïve and memory CD4+ and CD8+ T cells (Fig. 1C, representative plots), the effect was more pronounced on naïve T cells than on memory T cells for both CD4 and CD8 subsets (Fig. 1D, dark and light gray bars). In the absence of αCD3/αCD28, TGFβ1 does not affect the basal levels of PD-1 expression on either naïve or memory T-cell subsets. This suggests that TGFβ1 enhancement of PD-1 expression is dependent on T-cell activation. Furthermore, we found that TGFβ1 increased PD-1 surface expression in a concentration-dependent manner (Fig. 1E, left). In contrast, TGFβ1 did not affect the expression of the T-cell activation marker HLA-DR on T cells (Fig. 1E, right), demonstrating that the TGFβ1 effect on PD-1 expression does not simply reflect a general effect on T-cell activation–induced antigens. Changes in intracellular and surface levels of PD-1 were positively and directly correlated (Supplementary Fig. S1B). Finally, enhanced surface expression of PD-1 was preceded by increased transcription of PD-1, shown as kinetic changes of PDCD1 mRNA levels across different time points (Fig. 1F).

TGFβ Receptor I Kinase Activity Is Critical for TGFβ-Dependent Enhancement of PD-1 Expression

Next, we investigated whether blockade of TGFβ1 signaling can abrogate TGFβ-dependent PD-1 enhancement. TGFβ1 binds TGFβ receptor I (TGFβRI) and TGFβRII and acts through SMAD-dependent and SMAD-independent mechanisms (37). Upon binding of the high-affinity TGFβRII by TGFβ1, TGFβRI and TGFβRII heterodimerize and TGFβRI, a serine/threonine kinase, phosphorylates SMAD2/3. To address the role of TGFβ1 receptor signaling, the cells were activated in the presence of TGFβ1 with varying concentrations of either an antibody that blocks the activity of TGFβ1 but not TGFβ2 or TGFβ3 [neutralizing antibody (nAb); Fig. 2A] or a TGFβRI kinase inhibitor (SB431542; Fig. 2B). Both TGFβ1 nAb and SB431542 decreased TGFβ1-dependent PD-1 expression in a dose-dependent manner, although SB431542 was more effective than TGFβ1 nAb. SB431542-mediated TGFβR signaling inhibition was shown by the diminished phosphorylation levels of SMAD2 (Fig. 2C). Analogous to the effects on surface expression, SB431542 blocked the TGFβ1-dependent increase of PDCD1 mRNA levels (Fig. 2D). Given the critical role of nuclear factor of activated T cell (NFATc1) during TCR-dependent PD-1 induction (38), we tested whether TGFβ1-dependent PD-1 expression requires NFATc1 by treating cells with cyclosporine A, a calcineurin inhibitor that exerts its immunosuppressive effects by keeping the transcription factor NFATc1 inactive. We found that cyclosporine A completely abrogated not only TCR-dependent but also TGFβ1-enhanced PD-1 expression (Supplementary Fig. S1C), suggesting that TGFβ1 requires TCR-induced NFATc1 activity to enhance the PD-1 expression. On the basis of the critical role of TGFβR kinase activity, we next assessed downstream molecules in the TGFβR signaling cascade.

Figure 2.
Figure 2.

Anti-TGFβ1 neutralizing antibody and a TGFβRI kinase inhibitor negate TGFβ1-mediated PD-1 enhancement. A and B, Enriched human CD3+ T cells were activated with αCD3/αCD28–conjugated beads and TGFβ1 under varying concentrations of TGFβ1 nAb (A) or SB431542 (B) and PD-1 mean fluorescence intensity (MFI) was assessed. Closed circles, medium alone; open circles, αCD3/αCD28 only; closed triangles, αCD3/αCD28 + TGFβ1. The result shown is representative of at least three independent trials. C, Western blot analysis of phosphorylated SMAD2 (pSMAD2) in human CD3+ T cells treated with varying concentrations of TGFβRI kinase inhibitor (SB431542). D, Enriched human CD3+ T cells were activated with αCD3/αCD28–conjugated beads and TGFβ1 under increasing concentrations of SB431542. PDCD1 transcript levels in each condition were normalized to that of resting human CD3+ T cells. The result is shown as mean ± SEM of technical replicates and is representative of at least three independent trials.

TGFβ1-Dependent SMAD3 Regulates PDCD1 Promoter Activity

Our data suggest that human PD-1 expression is under direct transcriptional control by TGFβ1, so we hypothesized that TGFβ1 modulates human PDCD1 promoter activity. We identified putative SMAD-binding elements (SBE), one distal to (SBE-D) and the other proximal to (SBE-P) the PDCD1 transcription start site (Fig. 3A). To test this hypothesis, Jurkat T cells were transfected with a luciferase vector containing the 1.9 kb–long PDCD1 promoter region, and luciferase activity was measured after different treatments. αCD3/αCD28 activation induced PDCD1 promoter activity (Fig. 3B, gray bars), and mutation in the NFATc1-binding site abrogated such induction (Supplementary Fig. S1D and S1E). Because Jurkat T cells express minimal levels of the TGFβ receptors, the T cells were cotransfected with TGFβRI and TGFβRII plasmids (Supplementary Fig. S1F and S1G). The addition of TGFβ1 to αCD3/αCD28 enhanced NFATc1-dependent PDCD1 promoter activity (Fig. 3B, WT; and Supplementary Fig. S1F). The introduction of site-directed mutations in SBEs (shown in bold letters in Fig. 3A, named SBE-D and SBE-P) significantly diminished TGFβ1-driven PDCD1 promoter activity, and the introduction of both mutations (SBE-D/P) further decreased the effect (Fig. 3B). To further validate our luciferase-based reporter system, we utilized the chromatin immunoprecipitation (ChIP) assay to verify SMAD3 binding to the human PDCD1 promoter. Although αCD3/αCD28 did not induce SMAD3 binding, the addition of TGFβ1 significantly enhanced SMAD3 binding to the human PDCD1 promoter (Fig. 3C, right graph). This binding was specifically due to TGFβ1 receptor signaling, as it was abrogated by treatment with the TGFβRI kinase inhibitor SB431542 (Fig. 3C, right graph). There was no effect of TGFβ1 on binding of SMAD3 to the GAPDH promoter (Fig. 3C, left graph). We also confirmed that NFATc1 binds to the human PDCD1 promoter following αCD3/αCD28 stimulation and found that this binding was in fact enhanced by TGFβ1 (Supplementary Fig. S1H).

Figure 3.
Figure 3.

SMAD3 directly binds to the SBEs and regulates PDCD1 promoter activity. A, Schematic illustration of the proximal region of human PDCD1 promoter. Two SBEs are located at 1.2 kb (SBE-D) and 1.0 kb (SBE-P) upstream of the PDCD1 transcription start site. NFATc1 consensus sequence is located in immediate proximity to SBE-P. WT and mutated (Mut) sequences of both SBE-D and SBE-P are shown. B, Jurkat T cells were transfected with luciferase reporter vectors containing WT, mutant SBE-D, mutant SBE-P, and mutant SBE-D/P sequences of PDCD1 promoter (1.9 kb). After cotransfection with TGFβRI and TGFβRII expression plasmids, the cells were activated with plate-bound αCD3 and soluble αCD28 in the absence (gray bars) or presence (white bars) of TGFβ1 (50 ng/mL). NS, not significant. Luciferase activity was measured as described in the Methods section. C, Isolated human CD3+ T cells were activated under different conditions. White bars, medium alone; black bars, αCD3/αCD28 alone; hatched bars, αCD3/αCD28 with TGFβ1; gray bars, αCD3/αCD28 + TGFβ1 with SB431542. Immunoprecipitated DNA was subjected to qPCR, and fold enrichment of binding relative to IgG is shown as mean ± SEM of triplicate results. D, Jurkat T cells were cotransfected with 1.5 μmol/L of siRNA against SMAD2 or SMAD3, and PDCD1 promoter–driven luciferase activity was measured in relative luciferase units (ratio of firefly to Renilla luciferase activity). E, Transfected Jurkat T cells were treated with 10 μmol/L of specific inhibitor of SMAD3 (SIS3), and PDCD1 promoter–driven luciferase activity was measured after activation. The results are shown as mean ± SEM of technical replicates and are representative of at least three independent trials. The data were analyzed using two-way ANOVA and considered significant if *, P < 0.05.

TGFβR1 has serine/threonine kinase activity that phosphorylates SMAD2 and SMAD3 (39). SMAD2 and SMAD3 bifurcate the signaling pathway by forming heterodimers with SMAD4 (considered a co-SMAD; refs. 40, 41). Thus, we further investigated whether SMAD2 or SMAD3 is the dominant regulator of PDCD1 promoter activity by using siRNA (Supplementary Fig. S2A and S2B). We found that knockdown of SMAD3 expression (but not SMAD2) abrogated TGFβ1 enhancement of PDCD1 promoter activity (Fig. 3D). In addition, we tested whether a specific inhibitor of SMAD3, SIS3, that inhibits phosphorylation of SMAD3 but not SMAD2, affects PDCD1 promoter activity similarly to knockdown of SMAD3 (42). SIS3 inhibited TGFβ1 enhancement of PDCD1 promoter activity (Fig. 3E, white bars) without significantly altering NFATc1-dependent PDCD1 promoter activity (Fig. 3E, gray bars). Thus, our data collectively showed that SMAD3 is a key mediator of TGFβ1-enhanced PDCD1 promoter activity and increased PDCD1 transcription levels.

SMAD3-Dependent PD-1 Enhancement Is Conserved in Human and Murine T Cells

To investigate the role of SMAD3 on PD-1 T-cell surface expression, we treated human CD3+ cells with SIS3 and found that SIS3 treatment decreased PD-1 surface expression on both human CD4+ (Fig. 4A, left) and CD8+ (Fig. 4A, right) T cells in a dose-dependent manner. Next, we investigated whether SMAD3 deficiency can abrogate TGFβ1-dependent PD-1 expression on murine T cells. CD4+ T cells were isolated from WT, Smad2 f/f; Cd4-cre (Smad2 cKO), and Smad3 f/f; Cd4-Cre (Smad3 cKO) mice and activated with αCD3/αCD28 with or without TGFβ1 (Fig. 4b). Cre-mediated gene knockout of Smad2 and Smad3 in CD4+ T cells was confirmed by Western blot analysis (Supplementary Fig. S2C). Consistent with our human T-cell findings, TGFβ1 minimally increased PD-1 expression on Smad3 cKO CD4+ T cells compared with WT CD4+ T cells, as shown in both the representative histogram (Fig. 4B, left) and the mean fluorescence intensity (MFI) of PD-1 (Fig. 4B, right). In contrast, Smad2 cKO CD4+ T cells maintained high PD-1 expression in response to TGFβ1 (Fig. 4B). Similarly, when WT, Smad2 cKO, and Smad3 cKO OT-I [ovalbumin (Ova)-specific CD8+ T cells] cells were activated with type I Ova in the presence of TGFβ1, Smad3 cKO OT-I showed decreased PD-1 expression (Fig. 4C). In contrast, the expression of lymphocyte activation gene3 (LAG3), another inhibitory receptor, decreased on Smad3 cKO OT-I and OT-II (Ova-specific CD4+ T cells) cells activated in the presence of TGFβ1, suggesting that TGFβ1 has differential effects on inhibitory receptors (Supplementary Fig. S2D). Taken together, the in vitro results in both human and murine T cells support the notion that TGFβ1 enhancement of PD-1 transcription is dependent selectively on SMAD3.

Figure 4.
Figure 4.

TGFβ1-dependent SMAD3 enhances PD-1 expression on human and murine T cells. A, Human CD3+ T cells from healthy donors were isolated and pretreated with SIS3 at varying concentrations. Subsequently, the cells were activated with αCD3/αCD28–conjugated beads with or without TGFβ1. MFI of PD-1 expression in different conditions was assessed. Closed circles, αCD3/αCD28; open circles, αCD3/αCD28 + TGFβ1. The result shown is representative of at least three independent trials. B, CD4+ T cells were isolated from WT, Smad2 flox/flox (fl/fl); Cd4-cre (Smad2 cKO), Smad3 f/f; Cd4-cre (Smad3 cKO) mice and activated with plated-coated αCD3 and soluble αCD28 with or without TGFβ1 (50 ng/mL). NS, not significant. PD-1 expression is shown as overlaid histograms with shaded histogram (isotype control), thin histogram (αCD3/αCD28), and bold histogram (αCD3/αCD28 + TGFβ1). PD-1 MFI is also shown as mean ± SEM and represents combined results of two independent trials (bar graphs). C, Isolated WT, Smad2 cKO, and Smad3 cKO OT-I cells were activated with type I ovalbumin in the presence of irradiated splenocytes. PD-1 MFI is shown as mean ± SEM and represents combined results of two independent trials (bar graphs). D, Growth kinetics of B16 melanoma in WT (n = 7), Smad2 cKO (n = 10), and Smad3 cKO (n = 11) mice are shown as the mean volume ± SEM on different days. The data represent the combined results of two independent experiments. E, Average CD8+ PD-1+ percentages in Smad2 cKO and Smad3 cKO TILs are shown as normalized values to WT CD8+ PD-1+ percentages. The data were analyzed using the Student t test and considered significant if *, P < 0.05; **, P < 0.01, ***, P < 0.001.

Tumor-Infiltrating Smad3 cKO CD8+ T Cells Have Decreased PD-1 Expression

PD-1 is highly expressed on TILs, and its high expression is associated with decreased effector function in advanced-stage human cancer (3, 43–46). Given that TME-derived TGFβ1 can suppress antitumor immunity (30, 31), we hypothesized that SMAD3 contributes to high TIL PD-1 expression. To investigate whether TGFβ1 regulates PD-1 expression through SMAD3 in vivo, WT, Smad2 cKO, and Smad3 cKO mice were challenged with B16 melanoma, and PD-1 expression was assessed on TILs. SMAD2 and SMAD3 are known suppressors of T-cell function (33), and growth of B16 melanoma in Smad2 and Smad3 cKO mice was indeed significantly delayed (Fig. 4D). Although both Smad2 cKO and Smad3 cKO mice had comparably decreased volumes of B16 melanoma versus WT, the PD-1hi subset population was significantly lower on Smad3 cKO CD8+ TILs, but not on Smad2 cKO CD8+ (Fig. 4E). In contrast, LAG3 expression was significantly enhanced on Smad2 cKO CD8+ TILs but unaffected by Smad3 cKO (Supplementary Fig. S2E). PD-1 expression on CD4+ TILs was not significantly different among WT, Smad2, and Smad3 cKO groups, although the level of PD-1 expression was much lower on CD4 T cells than on CD8 T cells in all three mouse groups (Supplementary Fig. S2F). The lack of a significant difference in PD-1 expression on CD4+ T cells in vivo could be due to the minimal fraction of antigen-specific CD4+ effector T cells in the TME. Alternatively, because PD-1 is expressed by Tregs (47, 48) that constitute the majority of CD4+ TILs in B16 melanoma, most CD4+ TILs may not be specific for tumor antigens. Supporting this notion, we found that the majority of CD4+ PD-1+ TILs express FOXP3 (Supplementary Fig. S3A). However, in the presence of TCR signaling in vitro, FOXP3+ and FOXP3− CD4+ T cells are capable of enhancing PD-1 expression to the same extent in response to TGFβ1 (Supplementary Fig. S3B), and the FOXP3−CD4+ TILs did not express lower levels of PD-1 in the Smad3 cKO than in the WT mice (Supplementary Fig. S3C).

To test whether TGFβ1-induced SMAD3 activation upregulated PD-1 on tumor antigen–specific T cells, we utilized B16 melanoma cells stably expressing Ova as a model tumor antigen (B16-Ova). CD45.1 WT mice were challenged with B16-Ova and CD45.2 OT-I cells from WT, and Smad3 cKO OT-I mice were adoptively transferred into the tumor-bearing mice after tumor cells became palpable. The tumor growth was monitored, and lymphocytes infiltrating into tumors were harvested after 5 days. We found that transferred Smad3 cKO OT-I cells limit tumor growth more effectively than WT OT-I cells do (Fig. 5A). Consistent with our in vitro data, neither Smad3 cKO TILs nor Smad2 cKO TILs showed significantly increased cellular proliferation by CFSE (Fig. 5B and C) when gated on CD45.2+ (antigen experienced) donor cells. When a proliferated subset (i.e., CFSE-negative subset) was further gated, Smad3 cKO TILs showed significantly fewer of the PD-1hi–expressing T cells highly characteristic of WT TILs (Fig. 5D, top). This effect of SMAD3 was specific to PD-1, as there was no reduction in the LAG3hi subset in Smad3 cKO TILs (Fig. 5D, bottom). PD-1hi–expressing cells did not decrease in Smad2 cKO OT-I (Fig. 5E, top), further supporting that SMAD3 is a critical mediator of PD-1 expression in the TME. In contrast, Smad2 cKO TILs maintained high levels of PD-1 (Fig. 5E, top), which is consistent with our observation in polyclonal CD8+ T cells (Fig. 4E). Similar to TILs, LAG3 expression on OT-I cells was not significantly affected in Smad3 cKO mice. Conversely, PD-1 and LAG3 expression on T cells in DLNs and in non-DLNs (NDLN) was comparable between WT and Smad3 cKO OT-I (Supplementary Fig. S4A and S4B) or Smad2 cKO OT-I (Supplementary Fig. S4C and S4D), suggesting that the effect of TGFβ1 is specific to the TME. To confirm the specificity to the TME, WT and DNTGFβRII Tg+ mice were challenged with B16 melanoma, and tumor volume was measured. In association with enhanced antitumor immune responses in DNTGFβRII Tg+ mice (Supplementary Fig. S5A), decreased PD-1 expression was also observed on CD8+ TILs, but not on T cells from DLNs (Supplementary Fig. S5B). As in Smad2 and Smad3 cKO mice, the DNTGFβRII Tg+ mice did not show significant decreases in LAG3 expression on TIL or DLN T cells (Supplementary Fig. S5C).

Figure 5.
Figure 5.

Adoptive transfer of Smad3 cKO CD8+ T cells results in reduced tumor burden and PD-1hi subset relative to transfer of WT CD8+ T cells. A, Growth kinetics of B16-Ova in CD45.1 congenic mice that received no T cells (closed circles), WT OT-I (open circles), or Smad3 cKO OT-I (triangles). C57/BL6-expressing CD45.1 congenic markers were challenged with 1 × 105 B16-Ova melanoma cell line on day 0. On day 10, 107 CD45.2 CD8+ OT-I T cells from WT (n = 7) or Smad3 cKO (n = 5) mice were adoptively transferred into the mice with comparable tumor sizes. Tumor volume (mm3) is shown as mean ± SEM on different days, and the data represent combined results of two independent experiments. The data were analyzed using one-way ANOVA and considered significant if **, P < 0.01. B and C, CFSE-labeled tumor-infiltrating WT OT-I (top) or cKO OT-I (bottom) were isolated from B16-Ova 5 days after adoptive transfer, and TIL proliferation was assessed: Smad3 cKO (B) and Smad2 cKO OT-I (C). CD45.2+ donor population was gated from a plot of CD8 (y-axis) and CD45.2 (x-axis; left), and a representative histogram of CFSE (right) is shown from pooled TILs from n = 6 mice per group. D and E, contour plots of PD-1 (top) and LAG3 (bottom) among the proliferated cells (i.e., CFSE-negative populations) are shown as isotype (left), WT (middle), and cKO (right): Smad3 cKO (D) and Smad2 cKO (E). The data are representative of two independent experiments.

TGFβ1/SMAD3-Dependent Enhanced PD-1 Expression Is Associated with Decreased T-cell Function

We next assessed the effect of Smad2 and Smad3 cKO on T-cell function. The number of TILs obtained in the B16 model is smaller than in some other tumor models and isolation of TILs from the tumors harvested from the Smad2 and Smad3 cKO mice particularly challenging. To confirm our findings with B16 melanoma and to permit functional analysis of TILs and T cells from the DLNs, we used a cancer model with more abundant TILs, the MC38 colon cancer model. WT, Smad2 cKO, and Smad3 cKO mice were challenged with MC38 colon cancer, and PD-1 expression was assessed. As with the B16 melanoma (Fig. 4D), tumor growth in Smad2 and Smad3 cKO mice was significantly delayed (Fig. 6A). In contrast to CD8+ TILs, the PD-1hi subset population was absent in CD4+ TILs in all groups, and differences could not be assessed. As in B16 melanoma, the MFI of PD-1 on CD8+ TILs was significantly lower in the Smad3 cKO than in the WT or Smad2 cKO mice (Fig. 6B). We performed intracellular cytokine staining (ICS) to examine CD8+ T-cell production of IFNγ, TNFα, IL2, FOXP3, and granzyme B in WT and Smad3 cKO mice, but had insufficient TILs to perform ICS analysis for the Smad2 cKO group. We saw no significant differences between the Smad3 group and the WT group in FOXP3 or granzyme B levels when examining TILs or DLNs. However, in the Smad3 cKO group compared with the WT group, there was significantly higher production of TNFα from CD8+ TILs and of IFNγ and IL2 in the DLNs (Fig. 6C). Thus, decreased PD-1 expression secondary to the loss of Smad3 signaling in TILs and T cells in the DLNs is associated with increased production of multiple cytokines and functionality.

Figure 6.
Figure 6.

Loss of Smad3 in CD8+ T cells leads to enhanced cytokine production. A, Growth kinetics of MC-38 in WT (n = 7), Smad2 cKO (n = 6), or Smad3 cKO cells (n = 6) are shown as the mean volume ± SEM on different days. Data are representative from two independent experiments. The data were analyzed using one-way ANOVA and considered significant if **, P < 0.01; ***, P < 0.001. B, Average CD8+ CD44+ PD-1 MFI in Smad2 cKO and Smad3 cKO TILs are shown as normalized values to WT CD8+ PD-1+ percentages. NS, not significant. The data were analyzed using Student t test and considered significant if *, P < 0.05. C, Percentage of CD8 T cells producing IFNγ, TNFα, or IL2 in the spleen, DLNs, and tumor. The data were analyzed using the Student t test and considered significant if *, P < 0.05.

TGFβ1/SMAD3-Dependent Enhanced Antitumor Effects Involve PD-1 Expression

TGFβ1 is known to inhibit CD8+ T-cell effector function through SMAD2/3 (33) and many different mechanisms (37). Our data provide evidence that the enhancement of PD-1 expression represents a newly defined mechanism through which TGFβ1/SMAD3 suppresses T-cell function. To address how significant the impact of SMAD3-mediated PD-1 upregulation is on tumor evasion of T-cell responses, we treated Smad3 cKO mice bearing B16 melanoma with an anti–PD-1 blocking antibody (αPD-1) previously shown to have therapeutic efficacy in WT mice bearing B16 melanoma (49, 50). If the effect of Smad3 cKO on tumor growth is mediated through a mechanism other than PD-1 or if the effects of Smad3 cKO on PD-1 expression are not sufficient to negate that mechanism of tumor evasion, treatment with αPD-1 would confer additional therapeutic benefits in Smad3 cKO mice. To assess this, WT and Smad3 cKO mice were challenged with B16 melanoma cells and were given either isotype-matched IgG or αPD-1. We found that the tumor volume was decreased with αPD-1 compared with IgG-treated WT mice (Fig. 7, WT), attesting to the general role of the PD-1 pathway in immune resistance in this tumor model. In contrast, αPD-1 had no effect on tumor growth in Smad3 cKO mice (Fig. 7, Smad3).

Figure 7.
Figure 7.

Anti–PD-1 blocking antibody enhances antitumor immune responses in WT mice, but has minimal effect in Smad3-deficient mice. WT and Smad3 cKO were challenged with B16 melanoma cell line on day 0. WT and Smad3 cKO mice were treated with either isotype-matched control IgG (circles) or anti–PD-1 antibody (squares) from the day of tumor implantation until day 17. Tumor volume (mm3) on day 17 is shown as mean ± SEM, and the data represent combined results of two independent experiments. The data were analyzed using two-way ANOVA and considered significant if *, P < 0.05. NS, not significant.

Discussion

We show here that TGFβ1, signaling selectively through SMAD3, significantly upregulates PD-1 in the context of TCR engagement. We show that this mechanism is important in generating a PD-1hi population of T cells in the TME, where TGFβ1 expression is commonly very high. Thus, upregulation of both PD-1 ligands and the PD-1 receptor itself contributes to PD-1 pathway–mediated tumor immune resistance.

PD-1 expression can be differentially regulated by the environmental context in which a T cell encounters antigen. Upon activation, NFATc1 transiently induces PD-1 expression on T cells (38). Once PD-1 expression is induced, it is sustained in chronic infections or tolerogenic environments (2), but a high level of PD-1 expression is not achieved when antigen is encountered in an inflammatory environment, such as in Listeria monocytogenes infection (51). Further supporting the notion that the level of PD-1 expression is context dependent, there has been emerging evidence that cytokines can regulate NFATc1-induced PD-1 expression. IFNα promotes PD-1 expression on murine T cells through STAT1-mediated transcriptional regulation of Pdcd1 gene expression (21, 22). IL6 also increases PD-1 expression through a STAT3-dependent mechanism in murine CD8+ T cells in vitro (52), and we found similar regulation in human CD4+ and CD8+ T cells (Supplementary Fig. S1A). IL12 has differential effects on PD-1 in vivo and in vitro. IL12-conditioned tumor-specific memory CD8+ T cells have lower PD-1 expression in vivo with stronger antitumor immune responses (21). In contrast, we have found that IL12 increases PD-1 expression on human CD4+ and CD8+ T cells in vitro, consistent with others' findings on murine CD8+ T cells (52). Thus, although our data agree with the literature that IL6 and IL12 modulate PD-1 expression, TGFβ1 has the greatest effect on PD-1 expression, which has not been shown previously. The effects of some cytokines could be greater in vivo than we observed in vitro. However, our in vivo data demonstrating that the loss of TGFβ1 signaling has a profound impact on high-level PD-1 expression upon TCR engagement while signaling from other cytokines remains intact suggest that TGFβ1 signaling through SMAD3 is the major regulator of T-cell expression of PD-1 and function.

The data on the effect of other cytokines on PD-1 expression also collectively show that the regulatory mechanisms of PD-1 expression are highly conserved between human and mouse. This is further supported by high-sequence homology between human and murine Pdcd1 proximal promoter regions, including the NFATc1-binding site (52). We demonstrate that SMAD3-dependent PD-1 regulation is also conserved in showing that SMAD3 has the greatest effects on PD-1 expression on both human and murine T cells. NFATc1 was previously shown to be critical for PD-1 induction in mice (38), and mutation of antigens such that the TCR is no longer engaged results in a decline in human PD-1 expression in chronic infection with HCV or HIV (10, 53). Supporting previous findings that PD-1 expression depends on TCR engagement, we find that antigenic stimulation is required for TGFβ1 to enhance PD-1 expression and that NFATc1 binding to the human PDCD1 promoter following αCD3/αCD28 is enhanced by TGFβ1. Furthermore, TGFβ1 enhances PD-1 expression on both CD4+ and CD8+ T cells regardless of their naïve or memory status, although its effect was more pronounced on naïve T cells than on memory T cells.

Our proliferation assays showed that TGFβ1-mediated PD-1 enhancement is independent of cellular proliferation. In contrast to others' findings for which SMADs were proposed to play a role in TGFβ1 suppression of T-cell proliferation (54), we found that TGFβRI-dependent signaling, as demonstrated by phosphorylation of SMAD2 (Fig. 2C), did not result in suppression of T-cell proliferation. TGFβ1-mediated suppression of proliferation can be overcome by CD28-mediated costimulation, and it is possible that αCD3/αCD28 used in our in vitro culture system masked inhibition (55). However, neither Smad2 cKO OT-I nor Smad3 cKO OT-I showed significantly altered proliferation in vivo (Fig. 5B and C). Nevertheless, we observed that isolated Smad3 cKO CD4+ T cells have increased IL2 expression compared with WT littermates when activated with αCD3/αCD28 (Supplementary Fig. S5D), consistent with previous reports (56).

Others have suggested a potential association between TGFβ1 signaling and high PD-1 expression, but the direct causal relationship, the molecular mechanism, and biological implications of this association have not ever been characterized (32, 57, 58). TGFβ1 signaling consists of SMAD- and non-SMAD–dependent pathways, and SMAD-dependent gene regulation (SMAD2 and SMAD3) has been well characterized (59, 60). Some genes are preferentially and exclusively regulated by SMAD2 or SMAD3 as with ID1 and MYC (61, 62). On the other hand, SMAD2 and SMAD3 can redundantly regulate the expression of many genes that are under control of TGFβ1 (63). Our luciferase assay and in vitro data suggest that PD-1 regulation is predominantly under the control of Smad3. Although our in vitro data support a minor role for SMAD2 in TGFβ1-dependent PD-1 enhancement, our in vivo data clearly demonstrated no enhancement of PD-1 expression through SMAD2, with Smad2 cKO mice showing a small increase rather than decrease in PD-1 expression. The in vivo data could reflect enhanced SMAD3 activity in compensation for SMAD2 deletion in T cells.

Our in vivo studies mainly focused on CD8+ T cells because the PD-1 expression difference was greater in CD8+ T cells than in CD4+ T cells in vivo and the levels of PD-1 on CD4+ T cells much lower than on CD8+ T cells. Supporting this notion, TGFβ1-suppression of antitumor immunity in vivo appears to be dependent on CD8+ T cells but not on CD4+ T cells in a murine mouse model (31). This discrepancy could be due to cellular intrinsic difference between the CD4+ and CD8+ subsets of T cells (64). Our observation that stimulated OT-I and OT-II T cells respond similarly to TGFβ1 in vitro (Supplementary Fig. S2D) but CD4 and CD8 TILs in vivo do not may be explained by an absence of antigenic recognition by CD4+ TILs in vivo due to CD4+ T cells being primarily Tregs (Supplementary Fig. S3B and S3C). Alternatively, mechanisms of PD-1 regulation unique to CD4+ T cells may exist in vivo given that the FOXP3− CD4+ T cells in the Smad3 cKO mice did not express lower levels of PD-1 than WT (Supplementary Fig. S3D).

Interestingly, the effect of TGFβ1/SMAD3 on PD-1 expression of CD8+ T cells was specifically on TILs, but not on those originating from tumor DLNs. We did not find the percentage of PD-1hi T cells isolated from the tumor DLNs in WT mice to be significantly different from that of DNTGFβRII Tg+ and Smad3 cKO mice (Supplementary Figs. S4A and S4B and S5B). This may be due to the fact that the PD-1hi CD8+ T-cell population prominent in the TME was absent in DLNs in WT mice and suggests that TGFβ1 levels could be much lower outside of the TME. Supporting this notion, others found that TGFβ1 expression is higher in human head and neck squamous cell carcinoma tissue than in adjacent mucosal tissue (65). Nevertheless, it is yet to be determined whether the dominant source of TGFβ1 in the TME is derived from tumor or T cells. In spite of extensive evidence that TGFβ1 suppresses antitumor immunity, tumor-specific deletion of TGFβ1 did not enhance antitumor immune responses (33). In contrast, others have reported that the deletion of T cell–derived TGFβ1 was sufficient to prevent tumor growth (32).

Although Smad3 cKO mice did not mount immune responses as potent as those of DNTGFβRII Tg+ mice, B16 melanoma growth in Smad3 cKO mice appeared comparable with that in Pdcd1 KO mice or anti–PD-1 antibody–treated WT mice (Fig. 7). Although adoptive transfer of naïve antigen-specific T cells is known to confer minimal antitumor effects, transferred Smad3 cKO OT-I effectively controlled tumor growth (Fig. 5A). Collectively, these results provide direct evidence that PD-1–mediated antitumor immunity depends in part on Smad3 activation and that Smad3-driven PD-1 upregulation is relevant to tumor immune evasion. Our data clearly show that αPD-1 treatment decreases B16 tumor growth in WT mice (49, 50) but not in Smad3 cKO mice.

In summary, our data demonstrate a novel immunosuppressive function of TGFβ1 in regulating high-level PD-1 expression on T cells encountering cognate antigen. In addition to other suppressive roles for TGFβ1, TGFβ1 enriched in the TME may induce high levels of PD-1 on T cells as they encounter antigens on the tumor surface, reducing T-cell effector function and limiting the antitumor T-cell response. In addition, our data provide mechanistic understanding of the regulation of high-level PD-1 expression. Although it is well known that T cells against intact antigen in the setting of chronic viral infections, such as HCV and HIV, or malignancy express very high levels of PD-1, it is not known how those high levels are induced. This study elucidates a mechanism through which the highest levels of PD-1 are induced. Indeed, high TGFβ1 serum levels are associated with worse disease outcome in HCV infection (66), and TGFβ1 expression is high in the TME of advanced stages of cancer, which may further limit the efficacy of T cells against disease in those settings (67–69). Given the potential for autoimmunity with PD-1 therapy, it is worth investigating whether inhibitors of SMAD3 used in combination with other immunotherapeutic agents activate T cells expressing the highest levels of PD-1 rather than all T cells bearing PD-1. As the PD-1hi subset of TILs may in fact contain the highest proportion of true tumor-specific cells, these may be the most important target population for SMAD3 blockade.

Methods

Mice

All animals were housed and handled in compliance with Johns Hopkins Animal Care and Use policy. C57BL/6 DNTGFβRII Tg+ and C57BL/6 Cd4-Cre transgenic mice were purchased from The Jackson Laboratory. CD45.1 congenic mice were purchased from the NCI at Frederick, MD. Smad2 flox/flox (fl/fl) and Smad3 fl/fl mice were generated by S.-J. Lee's Laboratory at Johns Hopkins School of Medicine (Baltimore, MD) and backcrossed to C57BL/6 at least six generations. OT-I and OT-II mice were generous gifts from Drs. Charles Drake and Hyam Levitsky at Johns Hopkins School of Medicine. Age-matched female mice were utilized in all in vivo experiments.

Human and Murine Primary T-cell Isolation and Culture

Human PBMCs were isolated from leukopheresis by Ficoll–Hypaque density gradient. Isolated human PBMCs were subjected for CD3+ T-cell isolation using the Pan T-cell Isolation Kit (Miltenyi Biotec) as instructed in the manual. The isolated cells were activated for 72 hours with αCD3/αCD28 Dynabeads (Invitrogen) at a cell-to-bead ratio of 1:1 in RPMI + 10% FBS (supplemented with HEPES buffer, penicillin/streptomycin, and l-glutamine). Murine CD4+ and CD8+ T cells were isolated from the spleen and lymph nodes using the Negative Selection Kit (Invitrogen) and were activated with plate-coated αCD3 (10 μg/mL) and soluble αCD28 (2 μg/mL) or with cognate Ova peptides in the presence of irradiated splenocytes for 72 hours.

Transient Transfection and Luciferase Assay

Jurkat T cells (clone E6-1) were purchased from the ATCC and were kept as a frozen stock. Jurkat T cells (1.5 × 107) were transfected with 10 μg pGL-3 Firefly Luciferase Vector (Promega) and 1 μg of pRL-TK Vector (Promega) by electroporation using Nucleofector II (Amaxa/Lonza). The cells were rested in a 6-well plate overnight and activated with plate-coated αCD3 (10 μg/mL) and soluble αCD28 (5 μg/mL) with or without rhTGF-β1 (50 ng/mL). After 24 hours, the cells were harvested and lysed followed by luminescence measurement using Dual-Luciferase Assay (Promega). Where indicated, the cells were cotransfected with empty vector (pSG-V5), TGF-βRI-His (Addgene plasmid #19161), and TGF-βRII (Addgene plasmid #11766). For siRNA-mediated knockdown, the cells were cotransfected with 1.5 μmol/L of siRNA for SMAD2 (Santa Cruz Biotechnology, SC-38374) and SMAD3 (Santa Cruz Biotechnology, SC-38376).

Cytokine and Drug Treatments

Human recombinant IL1α, IL2, IL4, IL6, IL10, IL12, IL13, IL15, IL17, IL18, IL21, IL23, INFα, IFNγ, TGFβ1, and TNFα were purchased from Peprotech and used at 5, 50, and 500 ng/mL. The data shown in Supplementary Fig. S1A are using 500 ng/mL only because the relative effects of cytokines were not different at other doses. Primary human T cells were treated with neutralizing TGFβ1 antibody (Abcam, 2Ar2) and with small-molecule inhibitors SB431542, cyclosporine A (Sigma-Aldrich), and SIS3 (Calbiochem) for 1 hour prior to activation at the indicated concentration range.

Flow Cytometry

After indicated time of culture, human T cells were harvested and centrifuged at 400 × g (or 1,500 rpm) for 5 minutes. The cells were washed in FACS buffer (1× PBS + 2% FBS) and stained with Aqua Viability Dye (Invitrogen) as instructed in the manual. After wash, the cells were stained with PD-1 PE (BioLegend), CD8 PerCP, CD4 Pacific Blue, CD3 FITC (eBioscience), and HLA-DR APC (eBioscience) or qDot605 (Invitrogen). The similar protocol was used for murine T cells and PD-1 PE, CD4 or CD8 PerCP, FITC (eBioscience), LAG3 APC or PacBlue, CD4 BV605, CD8 BV570, CD3 AF700, PD-1 PE Cy7, and CD44 AF700 (BioLegend) were used for flow cytometry. For intracellular staining, the cells were treated with FOXP3/Transcription Factor Staining Buffet Set (eBioscience) and stained with FOXP3 FITC, TNFα PE (eBioscience), IL2 PE-CF594, or IFNγ APC (BD Biosciences).

Real-Time qPCR Assay

Total RNA was extracted from primary T cells under the indicated conditions using RNeasy Plus Kit (Qiagen). Extracted RNA (100 ng) was reverse transcribed using SuperScript III First-Strand Synthesis System (Invitrogen). Generated cDNA was subjected for real-time PCR assay. PDCD1 primer sequences are forward 5′-CACTGAGGCCTGAGGATGG-3′; reverse 5′-AGGGTCTGCAGAACACTGGT-3′. All target genes were normalized to 18s rRNA or 28s rRNA as described previously.

Molecular Cloning and Site-Directed Mutagenesis

Human PDCD1 promoter (1.9 kb) was cloned from the genomic DNA of isolated CD3+ T cells and the sequence was confirmed. The amplified clones were ligated to SacI/XhoI-digested pGL3-Basic Vector (Promega) using the In-Fusion Cloning Kit (Clontech). Site-directed mutagenesis was carried out using following primers for NFAT, SBE-D, and SBE-P sites using QuikChange Lightning Kit (Agilent Technologies). Primer sequences were as follows: forward: 5′-GATGCTCTTTTTGGACTGTTTCGG-3′, reverse 5′-CCGAAACAGTCCAAAAAGAGCATC-3′ (NFAT); forward: 5′-ACCTTAGCTGGATGGCAGCA-3′, reverse 5′-TGCTGCCATCCAGCTAAGGT-3′ (SBE-D); forward: 5′-CGCGCCTCGCATCCATCATCTT-3′, reverse: 5′-AAGATGATGGATGCGAGGCGCG-3′ (SBE-P).

ChIP Assay

ChIP assay was performed according to the manufacturer's guidance (Invitrogen MAGnify ChIP system). Briefly, isolated CD3+ T cells were activated with αCD3/αCD28–conjugated beads for 24 hours and fixed with 2% formaldehyde. Sonicated DNA was immunoprecipitated with αSMAD3 (Cell Signaling Technology), and αNFATc1 (Santa Cruz Biotechnology). The immunoprecipitated chromatin was analyzed on Roche LightCycler 480 by SYBR Green using the following primers for PDCD1 promoter. PDCD1: forward 5′-CCTCACATCTCTGAGACCCG-3′, reverse 5′-CCGAAGCGAGGCTAGAAACC-3′; GAPDH: 5′-TACTAGCGGTTTTACGGGCG-3′, 5′-TCGAACAGGAGGAGCAGAGAGCGA-3′.

Western Immunoblotting

Human or murine T cells were activated as indicated and harvested and lysed in RIPA Buffer (Cell Signaling Technology). Protein extract concentrations were measured using the BCA Protein Assay Kit (Thermo Scientific) and followed by heating under reducing conditions. The equal amounts of extracts were loaded/run on NuPAGE Precast gels (Invitrogen), and transferred membranes were blotted with the following antibodies: pSMAD2, total SMAD2, total SMAD3 (Cell Signaling Technology), and β-actin (Sigma).

B16 Melanoma and Adoptive T-cell Transfer Experiments

B16 melanoma cell lines were purchased from the ATCC and kept as frozen stock in 2014. B16 melanoma cell lines (1 × 105) were injected on a flank in 100 μL volume. Tumor volumes were measured every other day using a caliper and assessed using the formula 1/2 (length × width2). CD45.1 host mice were injected with 1 × 105 B16-Ova melanoma cell lines on a flank. WT OT-I or cKO OT-I (8 × 106) were labeled with the CellTrace CFSE Cell Proliferation Kit (Life Technologies) and were adoptively transferred into tumor-bearing mice by retro-orbital injection on day 12. The tumors were harvested on day 5 after the adoptive transfer, and lymphocytes were purified using Percoll (GE Healthcare) gradient. In a blocking experiment, 5 × 105 B16 melanoma cells were injected on a flank, and 100 μg Armenian hamster IgG isotype control (Rockland) or anti–PD-1 antibody (G4) were injected intraperitoneally twice a week from day 0. The B16 melanoma cell lines have tested negative for Mycoplasma but have not been authenticated by the laboratory.

MC38 Colon Adenocarcinoma Experiments

MC38 colon adenocarcinoma cell lines were purchased from the ATCC and kept as frozen stock. B16 melanoma cell lines (4 × 105) were injected on a flank in 100 μL volume. Tumor volumes were measured using a caliper and assessed using the formula ½ (length × width2). The tumors were harvested on day 23, and lymphocytes were purified using Percoll (GE Healthcare) gradient. For intracellular cytokine staining, lymphocytes were stimulated with phorbol 12-myristate 13-acetate (PMA, 50 ng/mL) and ionomycin (500 ng/mL) in the presence of Brefeldin A and Monensin (eBioscience) for 4 hours prior. After stimulation, cells were permeabilized and stained for intracellular cytokines. MC38 lines have tested negative for Mycoplasma but have not been authenticated by the laboratory.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: B.V. Park, F. Pan, A.L. Cox

Development of methodology: F. Pan

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B.V. Park, Z.T. Freeman, A. Ghasemzadeh, M.A. Chattergoon, A. Rutebemberwa, T.V. Huynh, S.M. Sebald, S.-J. Lee

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B.V. Park, Z.T. Freeman, A. Ghasemzadeh, M.A. Chattergoon, F. Pan

Writing, review, and/or revision of the manuscript: B.V. Park, A. Rutebemberwa, F. Pan, D.M. Pardoll, A.L. Cox

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Steigner, M.E. Winter, S.M. Sebald

Study supervision: F. Pan, A.L. Cox

Grant Support

This work was supported by grants U19 AI088791, R01AR060636, RO1AI099300, RO1AI089830, and P30CA006973 from the Bloomberg-Kimmel Institute for Cancer Immunotherapy and the National Institutes of Health.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

We would like to acknowledge Ada Tam and Richard L. Blosser from the Cancer Research Flow Cytometry Core and Tricia L. Nilles from the School of Public Health Flow Cytometry Core at Johns Hopkins University for their technical help. We are grateful to Juan Fu and Young Kim for providing anti–PD-1 antibody reagents and Xingmei Wu for maintaining and genotyping mouse colonies. Also, we want to thank the Jeff Wrana and Joan Massagué Laboratory for their generous donation of plasmids to Addgene.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Discovery Online (http://cancerdiscovery.aacrjournals.org/).

  • Received November 12, 2015.
  • Revision received September 23, 2016.
  • Accepted September 23, 2016.

References

  1. 1.↵
    1. Agata Y,
    2. Kawasaki A,
    3. Nishimura H,
    4. Ishida Y,
    5. Tsubat T,
    6. Yagita H,
    7. et al.
    Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765–72.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Barber DL,
    2. Wherry EJ,
    3. Masopust D,
    4. Zhu B,
    5. Allison JP,
    6. Sharpe AH,
    7. et al.
    Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682–87.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ahmadzadeh M,
    2. Johnson LA,
    3. Heemskerk B,
    4. Wunderlich JR,
    5. Dudley ME,
    6. White DE,
    7. et al.
    Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537–44.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Dong H,
    2. Strome SE,
    3. Salomao DR,
    4. Tamura H,
    5. Hirano F,
    6. Flies DB,
    7. et al.
    Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793–800.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Lipson EJ,
    2. Sharfman WH,
    3. Drake CG,
    4. Wollner I,
    5. Taube JM,
    6. Anders RA,
    7. et al.
    Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013;19:462–8
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Topalian SL,
    2. Hodi FS,
    3. Brahmer JR,
    4. Gettinger SN,
    5. Smith DC,
    6. McDermott DF,
    7. et al.
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Herbst RS,
    2. Soria JC,
    3. Kowanetz M,
    4. Fine GD,
    5. Hamid O,
    6. Gordon MS,
    7. et al.
    Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563–7.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ansell SM,
    2. Lesokhin AM,
    3. Borrello I,
    4. Halwani A,
    5. Scott EC,
    6. Gutierrez M,
    7. et al.
    PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311–9.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Day CL,
    2. Kaufmann DE,
    3. Kiepiela P,
    4. Brown JA,
    5. Moodley ES,
    6. Reddy S,
    7. et al.
    PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350–54.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Rutebemberwa A,
    2. Ray SC,
    3. Astemborski J,
    4. Levine J,
    5. Liu L,
    6. Dowd KA,
    7. et al.
    High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 2008;181:8215–25.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Boni C,
    2. Fisicaro P,
    3. Valdatta C,
    4. Amadei B,
    5. Di Vincenzo P,
    6. Giuberti T,
    7. et al.
    Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215–25.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Keir ME,
    2. Butte MJ,
    3. Freeman GJ,
    4. Sharpel AH
    . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Curiel TJ,
    2. Wei S,
    3. Dong H,
    4. Alvarez X,
    5. Cheng P,
    6. Mottram P,
    7. et al.
    Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562–7.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Taube JM,
    2. Anders RA,
    3. Young GD,
    4. Xu H,
    5. Sharma R,
    6. McMiller TL,
    7. et al.
    Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37–27ra37.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Kassel R,
    2. Cruise MW,
    3. Iezzoni JC,
    4. Taylor NA,
    5. Pruett TL,
    6. Hahn YS
    . Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology 2009;50:1625–37.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Ohigashi Y,
    2. Sho M,
    3. Yamada Y,
    4. Tsurui Y,
    5. Hamada K,
    6. Ikeda N,
    7. et al.
    Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947–53.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Thompson RH,
    2. Kuntz SM,
    3. Leibovich BC,
    4. Dong H,
    5. Lohse CM,
    6. Webster WS,
    7. et al.
    Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381–5.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Wu C,
    2. Zhu Y,
    3. Jiang J,
    4. Zhao J,
    5. Zhang XG,
    6. Xu N
    . Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006;108:19–24.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Pardoll DM
    . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Llosa NJ,
    2. Cruise M,
    3. Tam A,
    4. Wicks EC,
    5. Hechenbleikner EM,
    6. Taube JM,
    7. et al.
    The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43–51.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Gerner MY,
    2. Heltemes-Harris LM,
    3. Fife BT,
    4. Mescher MF
    . Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol 2013;191:1011–5.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Terawaki S,
    2. Chikuma S,
    3. Shibayama S,
    4. Hayashi T,
    5. Yoshida T,
    6. Okazaki T,
    7. et al.
    IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 2011;186:2772–9.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Shi Y,
    2. Massagué J
    . Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003;113:685–700.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Alatrakchi N,
    2. Graham CS,
    3. van der Vliet HJ,
    4. Sherman KE,
    5. Exley MA,
    6. Koziel MJ
    . Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol 2007;81:5882–92.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Cumont MC,
    2. Monceaux V,
    3. Viollet L,
    4. Lay S,
    5. Parker R,
    6. Hurtrel B,
    7. et al.
    TGF-beta in intestinal lymphoid organs contributes to the death of armed effector CD8 T cells and is associated with the absence of virus containment in rhesus macaques infected with the simian immunodeficiency virus. Cell Death Differ 2007;14:1747–58.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Penaloza-MacMaster P,
    2. Kamphorst AO,
    3. Wieland A,
    4. Araki K,
    5. Iyer SS,
    6. West EE,
    7. et al.
    Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med 2014;211:1905–18.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Li X,
    2. Yue ZC,
    3. Zhang YY,
    4. Bai J,
    5. Meng XN,
    6. Geng JS,
    7. et al.
    Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer. J Clin Lab Anal 2008;22:164–71.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Saito H,
    2. Tsujitani S,
    3. Oka S,
    4. Kondo A,
    5. Ikeguchi M,
    6. Maeta M,
    7. et al.
    An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000;20:4489–93.
    OpenUrlPubMed
  29. 29.↵
    1. Liu VC,
    2. Wong LY,
    3. Jang T,
    4. Shah AH,
    5. Park I,
    6. Yang X,
    7. et al.
    Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007;178:2883–92.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Kao JY,
    2. Gong Y,
    3. Chen CM,
    4. Zheng QD,
    5. Chen JJ
    . Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 2003;170:3806–11.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Gorelik L,
    2. Flavell RA
    . Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118–22.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Donkor MK,
    2. Sarkar A,
    3. Savage PA,
    4. Franklin RA,
    5. Johnson LK,
    6. Jungbluth AA,
    7. et al.
    T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity 2011;35:123–34
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Thomas DA,
    2. Massague J
    . TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8:369–80.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Chen W,
    2. Jin W,
    3. Hardegen N,
    4. Lei KJ,
    5. Li L,
    6. Marinos N,
    7. et al.
    Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875–86.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Bettelli E,
    2. Carrier Y,
    3. Gao W,
    4. Korn T,
    5. Strom TB,
    6. Oukka M,
    7. et al.
    Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235–8.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Duraiswamy J,
    2. Ibegbu CC,
    3. Masopust D,
    4. Miller JD,
    5. Araki K,
    6. Doho GH,
    7. et al.
    Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol 2011;186:4200–12.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Li MO,
    2. Wan YY,
    3. Sanjabi S,
    4. Robertson AK,
    5. Flavell RA
    . Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99–146.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Oestreich KJ,
    2. Yoon H,
    3. Ahmed R,
    4. Boss JM
    . NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 2008;181:4832–9.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Wrana JL,
    2. Attisano L,
    3. Carcamo J,
    4. Zentella A,
    5. Doody J,
    6. Laiho M,
    7. et al.
    TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992;71:1003–14.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Nagaraj NS,
    2. Datta PK
    . Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 2010;19:77–91.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Rubtsov YP,
    2. Rudensky AY
    . TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007;7:443–53.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Jinnin M,
    2. Ihn H,
    3. Tamaki K
    . Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 2006;69:597–607.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Sfanos KS,
    2. Bruno TC,
    3. Meeker AK,
    4. De Marzo AM,
    5. Isaacs WB,
    6. Drake CG
    . Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009;69:1694–703.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Thompson RH,
    2. Dong H,
    3. Lohse CM,
    4. Leibovich BC,
    5. Blute ML,
    6. Cheville JC,
    7. et al.
    PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007;13:1757–61.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Zhang Y,
    2. Huang S,
    3. Gong D,
    4. Qin Y,
    5. Shen Q
    . Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7:389–95.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Shi F,
    2. Shi M,
    3. Zeng Z,
    4. Qi RZ,
    5. Liu ZW,
    6. Zhang JY,
    7. et al.
    PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128:887–96.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Wang C,
    2. Li Y,
    3. Proctor TM,
    4. Vandenbark AA,
    5. Offner H
    . Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis. J Neurosci Res 2010;88:7–15.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Francisco LM,
    2. Salinas VH,
    3. Brown KE,
    4. Vanguri VK,
    5. Freeman GJ,
    6. Kuchroo VK,
    7. et al.
    PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206:3015–29.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Peng W,
    2. Liu C,
    3. Xu C,
    4. Lou Y,
    5. Chen J,
    6. Yang Y,
    7. et al.
    PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012;72:5209–18.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Woo SR,
    2. Turnis ME,
    3. Goldberg MV,
    4. Bankoti J,
    5. Selby M,
    6. Nirschl CJ,
    7. et al.
    Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72:917–27.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Goldberg MV,
    2. Maris CH,
    3. Hipkiss EL,
    4. Flies AS,
    5. Zhen L,
    6. Tuder RM,
    7. et al.
    Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007;110:186–92.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Austin JW,
    2. Lu P,
    3. Majumder P,
    4. Ahmed R,
    5. Boss JM
    . STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J Immunol 2014;192:4876–86.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Streeck H,
    2. Brumme ZL,
    3. Anastario M,
    4. Cohen KW,
    5. Jolin JS,
    6. Meier A,
    7. et al.
    Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 2008;5:e100.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. McKarns SC,
    2. Schwartz RH
    . Distinct effects of TGF-beta 1 on CD4+ and CD8+ T cell survival, division, and IL-2 production: a role for T cell intrinsic Smad3. J Immunol 2005;174:2071–83.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Sung JL,
    2. Lin JT,
    3. Gorham JD
    . CD28 co-stimulation regulates the effect of transforming growth factor-beta1 on the proliferation of naive CD4+ T cells. Int Immunopharmacol 2003;3:233–45.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. McKarns SC,
    2. Schwartz RH,
    3. Kaminski NE
    . Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol 2004;172:4275–84.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Tinoco R,
    2. Alcalde V,
    3. Yang Y,
    4. Sauer K,
    5. Zuniga EI
    . Cell-intrinsic transforming growth factor-β signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 2009;31:145–57.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Park HB,
    2. Paik DJ,
    3. Jang E,
    4. Hong S,
    5. Youn J
    . Acquisition of anergic and suppressive activities in transforming growth factor-beta-costimulated CD4+CD25- T cells. Int Immunol 2004;16:1203–13.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Derynck R,
    2. Zhang YE
    . Smad-dependent and Smad-independent pathways in TGF-[beta] family signalling. Nature 2003;425:577–84.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Gu A-D,
    2. Wang Y,
    3. Lin L,
    4. Zhang SS,
    5. Wan YY
    . Requirements of transcription factor Smad-dependent and -independent TGF-β signaling to control discrete T-cell functions. Proc Natl Acad Sci U S A 2012;109:905–10.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Liang Y-Y,
    2. Brunicardi FC,
    3. Lin X
    . Smad3 mediates immediate early induction of Id1 by TGF-[beta]. Cell Res 2009;19:140–48.
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Frederick JP,
    2. Liberati NT,
    3. Waddell DS,
    4. Shi Y,
    5. Wang XF
    . Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol 2004;24:2546–59.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Takimoto T,
    2. Wakabayashi Y,
    3. Sekiya T,
    4. Inoue N,
    5. Morita R,
    6. Ichiyama K,
    7. et al.
    Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J Immunol 2010;185:842–55.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Foulds KE,
    2. Zenewicz LA,
    3. Shedlock DJ,
    4. Jiang J,
    5. Troy AE,
    6. Shen H
    . Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol 2002;168:1528–32.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Lu SL,
    2. Reh D,
    3. Li AG,
    4. Woods J,
    5. Corless CL,
    6. Kulesz-Martin M,
    7. et al.
    Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 2004;64:4405–10.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    1. Guido M,
    2. De Franceschi L,
    3. Olivari N,
    4. Leandro G,
    5. Felder M,
    6. Corrocher R,
    7. et al.
    Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C. Mod Pathol 2006;19:1047–54.
    OpenUrlPubMed
  67. 67.↵
    1. Willimsky G,
    2. Czeh M,
    3. Loddenkemper C,
    4. Gellermann J,
    5. Schmidt K,
    6. Wust P,
    7. et al.
    Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008;205:1687–700.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    1. Javle M,
    2. Li Y,
    3. Tan D,
    4. Dong X,
    5. Chang P,
    6. Kar S,
    7. et al.
    Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer. PLoS One 2014;9:e85942.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. de Kruijf EM,
    2. Dekker TJ,
    3. Hawinkels LJ,
    4. Putter H,
    5. Smit VT,
    6. Kroep JR,
    7. et al.
    The prognostic role of TGF-beta signaling pathway in breast cancer patients. Ann Oncol 2013;24:384–90.
    OpenUrlAbstract/FREE Full Text
Back to top
View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Benjamin V. Park, Zachary T. Freeman, Ali Ghasemzadeh, Michael A. Chattergoon, Alleluiah Rutebemberwa, Jordana Steigner, Matthew E. Winter, Thanh V. Huynh, Suzanne M. Sebald, Se-Jin Lee, Fan Pan, Drew M. Pardoll and Andrea L. Cox
Cancer Discov December 1 2016 (6) (12) 1366-1381; DOI: 10.1158/2159-8290.CD-15-1347
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement